![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TATDN2 |
Gene summary for TATDN2 |
![]() |
Gene information | Species | Human | Gene symbol | TATDN2 | Gene ID | 9797 |
Gene name | TatD DNase domain containing 2 | |
Gene Alias | TATDN2 | |
Cytomap | 3p25.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A024R2F3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9797 | TATDN2 | HCC1_Meng | Human | Liver | HCC | 9.57e-23 | 2.62e-02 | 0.0246 |
9797 | TATDN2 | HCC1 | Human | Liver | HCC | 3.55e-02 | 3.04e+00 | 0.5336 |
9797 | TATDN2 | HCC2 | Human | Liver | HCC | 3.63e-11 | 3.27e+00 | 0.5341 |
9797 | TATDN2 | S015 | Human | Liver | HCC | 9.53e-09 | 3.46e-01 | 0.2375 |
9797 | TATDN2 | S016 | Human | Liver | HCC | 2.71e-04 | 2.45e-01 | 0.2243 |
9797 | TATDN2 | S027 | Human | Liver | HCC | 2.20e-03 | 4.49e-01 | 0.2446 |
9797 | TATDN2 | S028 | Human | Liver | HCC | 1.03e-17 | 6.03e-01 | 0.2503 |
9797 | TATDN2 | S029 | Human | Liver | HCC | 2.65e-12 | 4.77e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0090305 | Liver | HCC | nucleic acid phosphodiester bond hydrolysis | 152/7958 | 261/18723 | 1.90e-07 | 3.46e-06 | 152 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TATDN2 | SNV | Missense_Mutation | rs779863358 | c.625N>T | p.Arg209Trp | p.R209W | Q93075 | protein_coding | deleterious(0.01) | benign(0.332) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TATDN2 | SNV | Missense_Mutation | c.2203G>C | p.Glu735Gln | p.E735Q | Q93075 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
TATDN2 | insertion | In_Frame_Ins | novel | c.2123_2124insGCT | p.Ala708_Pro709insLeu | p.A708_P709insL | Q93075 | protein_coding | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
TATDN2 | insertion | Frame_Shift_Ins | novel | c.2126_2127insTGTGTTGGAGCCAGCCCTTGTCTGTGTTTACTGTGGAGTC | p.Tyr710ValfsTer57 | p.Y710Vfs*57 | Q93075 | protein_coding | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
TATDN2 | insertion | Nonsense_Mutation | novel | c.2128_2129insTGACCAATAATCATTAGCTATTATTACATTATATAGTTAAAAAAAGAG | p.Tyr710delinsLeuThrAsnAsnHisTerLeuLeuLeuHisTyrIleValLysLysArgAsp | p.Y710delinsLTNNH*LLLHYIVKKRD | Q93075 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
TATDN2 | deletion | Frame_Shift_Del | novel | c.95delN | p.Val32GlyfsTer24 | p.V32Gfs*24 | Q93075 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
TATDN2 | deletion | Frame_Shift_Del | novel | c.1215delN | p.Ala406ProfsTer11 | p.A406Pfs*11 | Q93075 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
TATDN2 | SNV | Missense_Mutation | c.2195N>T | p.Thr732Met | p.T732M | Q93075 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD | |
TATDN2 | SNV | Missense_Mutation | c.2144N>G | p.Gln715Arg | p.Q715R | Q93075 | protein_coding | tolerated(0.2) | possibly_damaging(0.628) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
TATDN2 | SNV | Missense_Mutation | c.2228C>A | p.Pro743Gln | p.P743Q | Q93075 | protein_coding | deleterious(0) | possibly_damaging(0.839) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |